GlassScriptPhysician profile
Christopher P DO
NPI 1346765955
$5,398.36
in general payments reported to CMS, 2019-2025
46 companies · $859 in 2025
The $859 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $314 · 2023: $1,466 · 2024: $2,570 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,697 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,696.76 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $430.57 | 2022-2024 | Lynparza, Enhertu, Imfinzi |
| Incyte Corporation | $343.24 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $331.31 | 2022-2025 | |
| Daiichi Sankyo INC. | $317.28 | 2022-2025 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $308.50 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $302.94 | 2021-2025 | Rybrevant, Carvykti, Imbruvica |
| Puma Biotechnology, INC. | $280.58 | 2023-2025 | |
| Eisai INC. | $261.24 | 2023-2025 | |
| Astellas Pharma US INC | $244.02 | 2024-2025 | Xtandi |
| Sobi, INC | $235.38 | 2023-2025 | |
| Pfizer INC. | $208.90 | 2021-2024 | |
| Pharmaessentia USA Corporation | $205.89 | 2023-2024 | Besremi |
| Novartis Pharmaceuticals Corporation | $172.88 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.94 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.57 | 2023-2024 | Fruzaqla |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $130.59 | 2023-2024 | Columvi, Polivy, Tecentriq |
| Gilead Sciences, INC. | $109.75 | 2023-2024 | |
| Exelixis INC. | $102.58 | 2023-2024 | Cabometyx |
| Glaxosmithkline, LLC. | $90.99 | 2022-2025 | Ojjaara, Blenrep |
| Coherus Oncology, INC. | $83.44 | 2023-2024 | |
| Adc Therapeutics America, INC. | $77.30 | 2024-2025 | |
| Genzyme Corporation | $69.20 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.49 | 2023-2024 | Gilotrif |
| Beigene USA, INC. | $59.34 | 2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $57.84 | 2023-2024 | Somatuline Depot, Onivyde |
| Rigel Pharmaceuticals, INC. | $51.55 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $50.10 | 2022-2023 | Imbruvica |
| Stemline Therapeutics INC. | $45.61 | 2023 | Orserdu |
| Karyopharm Therapeutics INC. | $45.61 | 2023-2024 | Xpovio |
| Deciphera Pharmaceuticals INC. | $44.09 | 2024-2025 | Qinlock, Romvimza |
| Lilly USA, LLC | $43.76 | 2024 | Jaypirca, Verzenio, Retevmo |
| Emd Serono, INC. | $38.74 | 2024 | |
| Mirati Therapeutics, INC. | $31.90 | 2024 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $29.62 | 2023-2024 | Opdualag |
| Alexion Pharmaceuticals, INC. | $28.35 | 2024 | Ultomiris |
| Fennec Pharmaceuticals, INC. | $23.09 | 2025 | Fyarro |
| Geron Corporation | $22.92 | 2025 | Rytelo |
| Seagen INC. | $22.49 | 2022 | |
| Morphosys, US INC. | $21.94 | 2023 | Monjuvi |
| Celgene Corporation | $21.72 | 2023 | Opdualag |
| Myriad Genetic Laboratories, INC. | $20.36 | 2024 | Myrisk |
| Agios Pharmaceuticals, INC. | $19.55 | 2024 | Pyrukynd |
| Recordati_rare_diseases_inc. | $18.69 | 2025 | Enjaymo |
| Cumberland Pharmaceuticals, INC. | $17.23 | 2024 | Sancuso |
| Aveo Pharmaceuticals, INC. | $16.23 | 2023 | Fotivda |
| Jazz Pharmaceuticals INC. | $16.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.